This content is from: United States

Was the Pfizer-Allergan merger proposal really a windfall for Ireland?

When new rules proposed by the US Treasury stopped the $160 billion Pfizer-Allergan super-inversion in early April many Americans applauded. Some grumbled about unfair tax loopholes or blamed Ireland’s 12.5% corporate tax for luring away American companies who pay up to 35% tax back home.

Get Free Access to read more …

Read the full article and get instant full access for free

Get Free Access
  • Full free access for a week in a few clicks
  • No commitments, no payment details
  • Featuring transfer pricing analysis

Are you ITR or TP week subscriber? Please log in.